Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2023-12-12 eCollection Date: 2023-01-01 DOI:10.1177/11795549231215968

Zexun Mo, Meifeng Ye, Hua He, Xiaomei Huang, Weihong Guo, Ziwen Zhao, Yujun Li, Shuquan Wei

{"title":"Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis.","authors":"Zexun Mo, Meifeng Ye, Hua He, Xiaomei Huang, Weihong Guo, Ziwen Zhao, Yujun Li, Shuquan Wei","doi":"10.1177/11795549231215968","DOIUrl":null,"url":null,"abstract":"Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered as the first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to analyze the efficacy of EGFR-TKIs treatment in patients with advanced NSCLC of different smoking habits.Methods: We conducted a search for meta-analyses and systematic reviews on the PubMed, MEDLINE, Embase, and the Cochrane Library to address this knowledge gap. Patients were divided into 2 groups: (1) experimental group: treated with EGFR-TKIs or EGFR-TKIs combined with chemotherapy, immunotherapy, antiangiogenesis, radiotherapy and (2) control group: treated with chemotherapy. Progressive-free survival (PFS) and total survival (OS) were adopted for evaluating the efficacy of EGFR-TKIs between experimental group and control group.Results: Eleven studies including 6760 patients were included in the meta-analysis. The results showed that smoking (including previous and current smoking) significantly reduces the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs. In addition, EGFR-TKIs combined with anti-vascular endothelial growth factor therapy can reduce the risk of disease progression in smokers.Conclusions: Our study indicated that smoking significantly reduced the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"17 ","pages":"11795549231215968"},"PeriodicalIF":1.9000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722912/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549231215968","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered as the first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to analyze the efficacy of EGFR-TKIs treatment in patients with advanced NSCLC of different smoking habits.

Methods: We conducted a search for meta-analyses and systematic reviews on the PubMed, MEDLINE, Embase, and the Cochrane Library to address this knowledge gap. Patients were divided into 2 groups: (1) experimental group: treated with EGFR-TKIs or EGFR-TKIs combined with chemotherapy, immunotherapy, antiangiogenesis, radiotherapy and (2) control group: treated with chemotherapy. Progressive-free survival (PFS) and total survival (OS) were adopted for evaluating the efficacy of EGFR-TKIs between experimental group and control group.

Results: Eleven studies including 6760 patients were included in the meta-analysis. The results showed that smoking (including previous and current smoking) significantly reduces the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs. In addition, EGFR-TKIs combined with anti-vascular endothelial growth factor therapy can reduce the risk of disease progression in smokers.

Conclusions: Our study indicated that smoking significantly reduced the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs.

查看原文本刊更多论文

吸烟习惯对晚期 NSCLC 患者接受 EGFR-TKI 治疗疗效的影响：系统回顾与元分析》。

背景：表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）被认为是晚期表皮生长因子受体突变阳性非小细胞肺癌（NSCLC）的一线治疗药物。我们旨在分析不同吸烟习惯的晚期NSCLC患者接受EGFR-TKIs治疗的疗效：我们在 PubMed、MEDLINE、Embase 和 Cochrane Library 上检索了荟萃分析和系统综述，以填补这一知识空白。患者分为两组：（1）实验组：接受表皮生长因子受体-TKIs或表皮生长因子受体-TKIs联合化疗、免疫治疗、抗血管生成治疗、放疗；（2）对照组：接受化疗。采用无进展生存期（PFS）和总生存期（OS）来评价实验组和对照组EGFR-TKIs的疗效：荟萃分析纳入了11项研究，包括6760名患者。结果表明，在使用 EGFR-TKIs 治疗 NSCLC 的过程中，与不吸烟组相比，吸烟（包括既往吸烟和当前吸烟）会明显降低 PFS 和 OS。此外，EGFR-TKIs联合抗血管内皮生长因子治疗可降低吸烟者的疾病进展风险：我们的研究表明，在使用表皮生长因子受体-TKIs治疗NSCLC的过程中，与非吸烟组相比，吸烟会明显降低患者的PFS和OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.